{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["4(2)"],"submitter":["Hofman V"],"pubmed_abstract":["<h4>Introduction</h4>Gene fusion testing of <i>ALK</i>, <i>ROS1</i>, <i>RET</i>, <i>NTRK</i>, and <i>MET</i> exon 14 skipping mutations is guideline recommended in nonsquamous NSCLC (NS-NSCLC). Nevertheless, assessment is often hindered by the limited availability of tissue and prolonged next-generation sequencing (NGS) testing, which can protract the initiation of a targeted therapy. Therefore, the development of faster gene fusion assessment is critical for optimal clinical decision-making. Here, we compared two ultrafast gene fusion assays (UFGFAs) using NGS (Genexus, Oncomine Precision Assay, Thermo Fisher Scientific) and a multiplex reverse-transcriptase polymerase chain reaction (Idylla, GeneFusion Assay, Biocartis) approach at diagnosis in a retrospective series of 195 NS-NSCLC case"],"journal":["JTO clinical and research reports"],"pagination":["100457"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9883235"],"repository":["biostudies-literature"],"pubmed_title":["Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC."],"pmcid":["PMC9883235"],"pubmed_authors":["Evrard S","Marquette CH","Begueret H","Allegra M","Caumont C","Barritault M","Vigier A","Brousset P","Benzerdjeb N","Lespinet-Fabre V","Bordone O","Boutros J","Salah M","Bontoux C","Benzaquen J","Tanga V","Bringuier PP","Fenouil T","Chalabreysse L","Heeke S","Hofman P","Hofman V","Merlio JP","Sabourin JC","Lassalle S","Ilie M","Long-Mira E","Syrykh C","Mazieres J","Bonnetaud C","Piton N"],"additional_accession":[]},"is_claimable":false,"name":"Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC.","description":"<h4>Introduction</h4>Gene fusion testing of <i>ALK</i>, <i>ROS1</i>, <i>RET</i>, <i>NTRK</i>, and <i>MET</i> exon 14 skipping mutations is guideline recommended in nonsquamous NSCLC (NS-NSCLC). Nevertheless, assessment is often hindered by the limited availability of tissue and prolonged next-generation sequencing (NGS) testing, which can protract the initiation of a targeted therapy. Therefore, the development of faster gene fusion assessment is critical for optimal clinical decision-making. Here, we compared two ultrafast gene fusion assays (UFGFAs) using NGS (Genexus, Oncomine Precision Assay, Thermo Fisher Scientific) and a multiplex reverse-transcriptase polymerase chain reaction (Idylla, GeneFusion Assay, Biocartis) approach at diagnosis in a retrospective series of 195 NS-NSCLC case","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-21T22:37:00.483Z","creation":"2025-04-05T18:48:54.443Z"},"accession":"S-EPMC9883235","cross_references":{"pubmed":["36718140"],"doi":["10.1016/j.jtocrr.2022.100457"]}}